{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:46:12Z","timestamp":1789962372225,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clazosentan, a selective endothelin A receptor antagonist, mitigates cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). Although it reduces vasospasm-related events,\u00a0it is also associated with adverse events (AEs) related to fluid retention, which are hypothesized to stem from systemic capillary leaks. These AEs often necessitate early discontinuation of therapy. This study aimed to identify early clinical markers of clazosentan intolerance, specifically focusing on fluid balance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This sub-analysis utilized data from the RECOVER registry, focusing on 208 patients diagnosed with aSAH who received clazosentan. Postoperative fluid status was quantified by calculating the mean daily fluid balance during postoperative days (POD) 1\u20133. The primary endpoint was discontinuation of clazosentan because of AEs. To identify independent predictors, a multivariable logistic regression analysis was conducted.\u00a0A favorable outcome was defined as a modified Rankin Scale score of 0\u20132 at discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 31 (14.9%) patients discontinued clazosentan on POD 6 [interquartile range (IQR), 3\u201310]. Discontinuation was most frequently attributed to worsening respiratory status (13\/31, 41.9%), consistent with fluid overload. During POD 1\u20133, fluid intake was comparable between groups, whereas urine output was lower in those who discontinued treatment, yielding an early positive balance. Spline analysis showed a sharp risk rise beyond\u2009+\u2009750\u00a0mL\/day; dichotomization at this threshold confirmed an independent association with discontinuation [\u2265\u2009+750\u00a0mL\/day: adjusted odds ratio (OR), 3.41; 95% confidence interval (CI), 1.29\u20138.92;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). Discontinuation was associated with lower odds of a favorable outcome (46.7% vs. 68.6%; adjusted OR, 0.40; 95% CI 0.18\u20130.88;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early positive fluid balance was a strong independent predictor of clazosentan discontinuation and was associated with poor functional outcomes. Early postoperative fluid balance may serve as a practical bedside marker of clazosentan intolerance and fluid-retentive physiological response, potentially involving increased vascular permeability. Goal-directed fluid management targeting euvolemia during the first 72\u00a0h may help optimize tolerability and enhance the therapeutic efficacy of clazosentan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12028-026-02476-5","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:58:33Z","timestamp":1774367913000},"page":"327-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early Positive Fluid Balance as a Clinical Marker of Systemic Capillary Leak and Clazosentan Intolerance After Aneurysmal Subarachnoid Hemorrhage"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4225-110X","authenticated-orcid":false,"given":"Shinsuke","family":"Muraoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2476_CR1","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S, Chou SHY, Cruz-Flores S, Dangayach NS, et\u00a0al. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American heart association\/American stroke association. Stroke. 2023;54:e314\u201370. https:\/\/doi.org\/10.1161\/STR.0000000000000436.","journal-title":"Stroke"},{"key":"2476_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1681\/ASN.2005121256","volume":"17","author":"N Dhaun","year":"2006","unstructured":"Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol. 2006;17:943\u201355. https:\/\/doi.org\/10.1681\/ASN.2005121256.","journal-title":"J Am Soc Nephrol"},{"key":"2476_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/bcp.12064","volume":"76","author":"DE Kohan","year":"2013","unstructured":"Kohan DE, Pollock DM. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol. 2013;76:573\u20139. https:\/\/doi.org\/10.1111\/bcp.12064.","journal-title":"Br J Clin Pharmacol"},{"key":"2476_CR4","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/STROKEAHA.108.519942","volume":"39","author":"RL Macdonald","year":"2008","unstructured":"Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et\u00a0al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39:3015\u201321. https:\/\/doi.org\/10.1161\/STROKEAHA.108.519942.","journal-title":"Stroke"},{"key":"2476_CR5","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(11)70108-9","volume":"10","author":"RL Macdonald","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et\u00a0al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10:618\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(11)70108-9.","journal-title":"Lancet Neurol"},{"key":"2476_CR6","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","volume":"43","author":"RL Macdonald","year":"2012","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et\u00a0al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43:1463\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.111.648980.","journal-title":"Stroke"},{"key":"2476_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3171\/2022.2.JNS212914","volume":"137","author":"H Endo","year":"2022","unstructured":"Endo H, Hagihara Y, Kimura N, Takizawa K, Niizuma K, Togo O, et\u00a0al. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022;137:1707\u201317. https:\/\/doi.org\/10.3171\/2022.2.JNS212914.","journal-title":"J Neurosurg"},{"key":"2476_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1413632","volume":"15","author":"H Sakata","year":"2024","unstructured":"Sakata H, Kanoke A, Uchida H, Haryu S, Omodaka S, Kimura N, et\u00a0al. Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study. Front Neurol. 2024;15:1413632. https:\/\/doi.org\/10.3389\/fneur.2024.1413632.","journal-title":"Front Neurol"},{"key":"2476_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.116.234930","volume":"361","author":"M Vercauteren","year":"2017","unstructured":"Vercauteren M, Trensz F, Pasquali A, Cattaneo C, Strasser DS, Hess P, et\u00a0al. Endothelin ETA, receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention. J Pharmacol Exp Ther. 2017;361:322\u201333. https:\/\/doi.org\/10.1124\/jpet.116.234930.","journal-title":"J Pharmacol Exp Ther"},{"key":"2476_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3171\/2025.1.JNS242509","volume":"143","author":"S Muraoka","year":"2025","unstructured":"Muraoka S, Izumi T, Nishida K, Chr\u00e9tien B, Ishii K, Takeuchi I, et\u00a0al. RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2025;143:624\u201333. https:\/\/doi.org\/10.3171\/2025.1.JNS242509.","journal-title":"J Neurosurg"},{"key":"2476_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000910092.27026.60","volume":"51","author":"T Jones","year":"2023","unstructured":"Jones T, Cutchins C, Sikora A. Effects of early use of loop diuretics on fluid balance in critically ill patients. Crit Care Med. 2023;51:541. https:\/\/doi.org\/10.1097\/01.CCM.0000910092.27026.60.","journal-title":"Crit Care Med"},{"key":"2476_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.731641","volume":"9","author":"H Schenck","year":"2021","unstructured":"Schenck H, Netti E, Teernstra O, De Ridder I, Dings J, Niemel\u00e4 M, et\u00a0al. The role of the glycocalyx in the pathophysiology of subarachnoid hemorrhage-induced delayed cerebral ischemia. Front Cell Dev Biol. 2021;9:731641. https:\/\/doi.org\/10.3389\/fcell.2021.731641.","journal-title":"Front Cell Dev Biol"},{"key":"2476_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13613-023-01145-9","volume":"13","author":"B Saravi","year":"2023","unstructured":"Saravi B, Goebel U, Hassenzahl LO, Jung C, David S, Feldheiser A, et\u00a0al. Capillary leak and endothelial permeability in critically ill patients: A current overview. Ann Intensive Care. 2023;13:105. https:\/\/doi.org\/10.1186\/s13613-023-01145-9.","journal-title":"Ann Intensive Care"},{"key":"2476_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073645","volume":"23","author":"JL Wautier","year":"2022","unstructured":"Wautier JL, Wautier MP. Vascular permeability in diseases. Int J Mol Sci. 2022;23:3645. https:\/\/doi.org\/10.3390\/ijms23073645.","journal-title":"Int J Mol Sci"},{"key":"2476_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121935","volume":"11","author":"KEM Hellenthal","year":"2022","unstructured":"Hellenthal KEM, Brabenec L, Wagner NM. Regulation and dysregulation of endothelial permeability during systemic inflammation. Cells. 2022;11:1935. https:\/\/doi.org\/10.3390\/cells11121935.","journal-title":"Cells"},{"key":"2476_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00395-010-0118-z","volume":"105","author":"BF Becker","year":"2010","unstructured":"Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010;105:687\u2013701. https:\/\/doi.org\/10.1007\/s00395-010-0118-z.","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"2476_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1161\/01.RES.0000090994.15442.42","volume":"93","author":"T Carpenter","year":"2003","unstructured":"Carpenter T, Schomberg S, Steudel W, Ozimek J, Colvin K, Stenmark K, et\u00a0al. Endothelin B receptor deficiency predisposes to pulmonary edema formation via increased lung vascular endothelial cell growth factor expression. Circ Res. 2003;93(5):456\u201363. https:\/\/doi.org\/10.1161\/01.RES.0000090994.15442.42.","journal-title":"Circ Res"},{"key":"2476_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/00006123-200109000-00012","volume":"49","author":"A Egge","year":"2001","unstructured":"Egge A, Waterloo K, Sj\u00f8holm H, Solberg T, Ingebrigtsen T, Romner B. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery. 2001;49:593\u2013605. https:\/\/doi.org\/10.1097\/00006123-200109000-00012. (discussion 605).","journal-title":"Neurosurgery"},{"key":"2476_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/01.STR.31.2.383","volume":"31","author":"L Lennihan","year":"2000","unstructured":"Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, et\u00a0al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31:383\u201391. https:\/\/doi.org\/10.1161\/01.STR.31.2.383.","journal-title":"Stroke"},{"key":"2476_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12028-023-01713-5","volume":"39","author":"MM Treggiari","year":"2023","unstructured":"Treggiari MM, Rabinstein AA, Busl KM, Caylor MM, Citerio G, Deem S, et\u00a0al. Guidelines for the neurocritical care management of aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2023;39:1\u201328. https:\/\/doi.org\/10.1007\/s12028-023-01713-5.","journal-title":"Neurocrit Care"},{"key":"2476_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103403","volume":"14","author":"S Muraoka","year":"2025","unstructured":"Muraoka S, Izumi T, Nishihori M, Goto S, Takeuchi I, Saito R. Emerging advances in the management of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a narrative review. J Clin Med. 2025;14:3403. https:\/\/doi.org\/10.3390\/jcm14103403.","journal-title":"J Clin Med"},{"key":"2476_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3171\/2024.4.JNS232191","volume":"142","author":"SA Mayer","year":"2024","unstructured":"Mayer SA, Bruder N, Citerio G, Defreyne L, Dubois C, Gupta R, et\u00a0al. REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2024;142:98\u2013109. https:\/\/doi.org\/10.3171\/2024.4.JNS232191.","journal-title":"J Neurosurg"},{"key":"2476_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-023-02104-2","volume":"46","author":"S Muraoka","year":"2023","unstructured":"Muraoka S, Asai T, Fukui T, Ota S, Shimato S, Koketsu N, et\u00a0al. Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. Neurosurg Rev. 2023;46:195. https:\/\/doi.org\/10.1007\/s10143-023-02104-2.","journal-title":"Neurosurg Rev"},{"key":"2476_CR24","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1161\/STROKEAHA.107.484634","volume":"38","author":"T Mutoh","year":"2007","unstructured":"Mutoh T, Kazumata K, Ajiki M, Ushikoshi S, Terasaka S. Goal-directed fluid management by bedside transpulmonary hemodynamic monitoring after subarachnoid hemorrhage. Stroke. 2007;38:3218\u201324. https:\/\/doi.org\/10.1161\/STROKEAHA.107.484634.","journal-title":"Stroke"},{"key":"2476_CR25","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1161\/STROKEAHA.109.547463","volume":"40","author":"T Mutoh","year":"2009","unstructured":"Mutoh T, Kazumata K, Ishikawa T, Terasaka S. Performance of bedside transpulmonary thermodilution monitoring for goal-directed hemodynamic management after subarachnoid hemorrhage. Stroke. 2009;40:2368\u201374. https:\/\/doi.org\/10.1161\/STROKEAHA.109.547463.","journal-title":"Stroke"},{"key":"2476_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/SHK.0b013e31826a3813","volume":"38","author":"A Watanabe","year":"2012","unstructured":"Watanabe A, Tagami T, Yokobori S, Matsumoto G, Igarashi Y, Suzuki G, et\u00a0al. Global end-diastolic volume is associated with the occurrence of delayed cerebral ischemia and pulmonary edema after subarachnoid hemorrhage. Shock. 2012;38:480\u20135. https:\/\/doi.org\/10.1097\/SHK.0b013e31826a3813.","journal-title":"Shock"},{"issue":"1","key":"2476_CR27","doi-asserted-by":"publisher","first-page":"H242","DOI":"10.1152\/ajpheart.00342.2020","volume":"319","author":"AV Kuczmarski","year":"2020","unstructured":"Kuczmarski AV, Shoemaker LN, Hobson JC, Edwards DG, Wenner MM. Altered endothelial ETB receptor expression in postmenopausal women. Am J Physiol Heart Circ Physiol. 2020;319(1):H242\u20137. https:\/\/doi.org\/10.1152\/ajpheart.00342.2020.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"2476_CR28","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/HCO.0b013e328302f3c6","volume":"23","author":"BL Stauffer","year":"2008","unstructured":"Stauffer BL, Westby CM, DeSouza CA. Endothelin-1, aging and hypertension. Curr Opin Cardiol. 2008;23(4):350\u20135. https:\/\/doi.org\/10.1097\/HCO.0b013e328302f3c6.","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"2476_CR29","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s11357-020-00303-8","volume":"43","author":"AP Young","year":"2021","unstructured":"Young AP, Draznin MB, Davy KP, et\u00a0al. The influence of menopause and sex hormones on endothelin-1 in the vasculature and the relevance to cardiovascular disease. GeroScience. 2021;43(4):1447\u201363. https:\/\/doi.org\/10.1007\/s11357-020-00303-8. (PMID:33403617).","journal-title":"GeroScience"},{"issue":"1","key":"2476_CR30","doi-asserted-by":"publisher","first-page":"H110","DOI":"10.1152\/ajpheart.00621.2023","volume":"326","author":"S Tummala","year":"2024","unstructured":"Tummala S, Kuczmarski AV, Del Vecchio AR, Schwab AI, Edwards DG, Wenner MM. Antecubital venous endothelial ETB receptor protein expression is preserved with aging in men. Am J Physiol Heart Circ Physiol. 2024;326(1):H110\u20135. https:\/\/doi.org\/10.1152\/ajpheart.00621.2023.","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02476-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-026-02476-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02476-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:26:20Z","timestamp":1784049980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-026-02476-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1007\/s12028-026-02476-5","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Nagoya University Hospital (approval no. 2022\u20130476), and the requirement for informed consent was waived. All study procedures were conducted in accordance with the Declaration of Helsinki, and the study reporting adhered to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}